Format

Send to

Choose Destination
Fertil Steril. 2001 Jan;75(1):18-22.

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix.

Author information

1
Department of Gynecology and Obstetrics, Medical University of Lübeck, Lübeck, Germany. ludwig_m@t-online.de

Abstract

OBJECTIVE:

To summarize data from completed phase II and III clinical trials on children born after controlled ovarian stimulation using the luteinizing hormone-releasing hormone antagonist cetrorelix.

DESIGN:

All children born after ovarian stimulation in patients treated for infertility who were in prospective studies until March 23, 1999.

SETTING:

Academic research center.

PATIENT(S):

Children born after IVF or IVF plus ICSI.

INTERVENTION(S):

Controlled ovarian stimulation with cetrorelix in a multiple-dose or single/dual-dose protocol.

MAIN OUTCOME MEASURE(S):

Outcome of pregnancy and, in deliveries, the date of birth, number and sex of children born, birth weight, body length, and abnormalities were recorded. At approximately 1 year of age and 2 years of age, body weight and length and abnormalities in physical and mental development were recorded.

RESULT(S):

Two hundred nine and 18 children were born after fresh and frozen embryo transfers, respectively. Of the pregnancies, 76.2% (179 of 234) resulted in live birth and ectopic pregnancy occurred in 3.4% (8 of 231); one heterotopic pregnancy and four induced abortions were recorded. The malformation rate among all live births, stillbirths, and aborted fetuses was 3.1%.

CONCLUSION(S):

Use of cetrorelix in controlled ovarian stimulation does not harm the subsequently born children.

PMID:
11163811
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center